226 related articles for article (PubMed ID: 16649823)
1. An open-label trial of risperidone augmentation for refractory anxiety disorders.
Simon NM; Hoge EA; Fischmann D; Worthington JJ; Christian KM; Kinrys G; Pollack MH
J Clin Psychiatry; 2006 Mar; 67(3):381-5. PubMed ID: 16649823
[TBL] [Abstract][Full Text] [Related]
2. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial.
Katzman MA; Vermani M; Jacobs L; Marcus M; Kong B; Lessard S; Galarraga W; Struzik L; Gendron A
J Anxiety Disord; 2008 Dec; 22(8):1480-6. PubMed ID: 18455360
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study.
Brawman-Mintzer O; Knapp RG; Nietert PJ
J Clin Psychiatry; 2005 Oct; 66(10):1321-5. PubMed ID: 16259547
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).
Vieta E; Herraiz M; Fernández A; Gastó C; Benabarre A; Colom F; Martínez-Arán A; Reinares M
J Clin Psychiatry; 2001 Aug; 62(8):623-30. PubMed ID: 11561935
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder.
Hoge EA; Worthington JJ; Kaufman RE; Delong HR; Pollack MH; Simon NM
CNS Spectr; 2008 Jun; 13(6):522-7. PubMed ID: 18567977
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review.
Gao K; Muzina D; Gajwani P; Calabrese JR
J Clin Psychiatry; 2006 Sep; 67(9):1327-40. PubMed ID: 17017818
[TBL] [Abstract][Full Text] [Related]
7. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Sheehan DV; McElroy SL; Harnett-Sheehan K; Keck PE; Janavs J; Rogers J; Gonzalez R; Shivakumar G; Suppes T
J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
[TBL] [Abstract][Full Text] [Related]
8. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H
J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250
[TBL] [Abstract][Full Text] [Related]
9. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
Bandelow B; Baldwin DS; Dolberg OT; Andersen HF; Stein DJ
J Clin Psychiatry; 2006 Sep; 67(9):1428-34. PubMed ID: 17017830
[TBL] [Abstract][Full Text] [Related]
10. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study.
Prosser JM; Yard S; Steele A; Cohen LJ; Galynker II
BMC Psychiatry; 2009 May; 9():25. PubMed ID: 19470174
[TBL] [Abstract][Full Text] [Related]
11. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
Nierenberg AA; Ostacher MJ; Calabrese JR; Ketter TA; Marangell LB; Miklowitz DJ; Miyahara S; Bauer MS; Thase ME; Wisniewski SR; Sachs GS
Am J Psychiatry; 2006 Feb; 163(2):210-6. PubMed ID: 16449473
[TBL] [Abstract][Full Text] [Related]
12. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.
Turgay A; Binder C; Snyder R; Fisman S
Pediatrics; 2002 Sep; 110(3):e34. PubMed ID: 12205284
[TBL] [Abstract][Full Text] [Related]
14. An open-label study of levetiracetam for the treatment of social anxiety disorder.
Simon NM; Worthington JJ; Doyle AC; Hoge EA; Kinrys G; Fischmann D; Link N; Pollack MH
J Clin Psychiatry; 2004 Sep; 65(9):1219-22. PubMed ID: 15367048
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study.
Maina G; Albert U; Rosso G; Bogetto F
J Clin Psychiatry; 2008 Apr; 69(4):609-16. PubMed ID: 18294024
[TBL] [Abstract][Full Text] [Related]
16. International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: II. Pharmacotherapy of anxiety disorders.
Uhlenhuth EH; Balter MB; Ban TA; Yang K
J Affect Disord; 1995 Dec; 35(4):153-62. PubMed ID: 8749980
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder.
Adams JB; Pyke RE; Costa J; Cutler NR; Schweizer E; Wilcox CS; Wisselink PG; Greiner M; Pierce MW; Pande AC
J Clin Psychopharmacol; 1995 Dec; 15(6):428-34. PubMed ID: 8748432
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder.
Seo JS; Jamieson K; Cosgrove V; Gwizdowski IS; Yang H; Sheehan DV; McElroy SL; Suppes T
Eur Psychiatry; 2013 Mar; 28(3):190-6. PubMed ID: 22130178
[TBL] [Abstract][Full Text] [Related]
20. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial.
Simon NM; Otto MW; Worthington JJ; Hoge EA; Thompson EH; Lebeau RT; Moshier SJ; Zalta AK; Pollack MH
J Clin Psychiatry; 2009 Nov; 70(11):1563-70. PubMed ID: 19814948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
